Achieving equitable access to incretin-based therapies in cardiovascular care

被引：0
作者：
Reddy, Tina K. [1 ]
Villavaso, Chloe D. [2 ]
Pulapaka, Anuhya V. [2 ]
Ferdinand, Keith C. [2 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD USA
[2] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA
来源：
AMERICAN HEART JOURNAL PLUS: CARDIOLOGY RESEARCH AND PRACTICE | 2024年 / 46卷
关键词：
Incretin-based therapy; Obesity; Diabetes; Hypertension; Cardiovascular disease; Racial/ethnic disparities; PREVENTION; WEIGHT;
D O I：
10.1016/j.ahjo.2024.100455
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The role of incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP1RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, in the management of type 2 diabetes mellitus (T2DM) and obesity has been increasingly recognized, along with significant cardiovascular (CV) benefits. Despite the clinical efficacy of incretin-based therapies, high costs, suboptimal access, limited insurance coverage, and therapeutic inertia present substantial barriers to widespread adoption. Overcoming these obstacles is essential for the equitable initiation, access, and utilization of incretin-based therapies. Clinicians must make targeted efforts to ensure health equity in the use of these and other advanced therapies.
引用
收藏
页数：7
相关论文
共 49 条
  • [1] [Anonymous], Real-world analysis of GLP-1a drugs for weight loss finds low adherence and increased cost in first year
  • [2] [Anonymous], Costly GLP-1 Drugs are Rarely Covered for Weight Loss by Marketplace Plans
  • [3] [Anonymous], MEDICATIONS CONTAINI
  • [4] [Anonymous], 2024, Combating implicit bias and stereotypes Think Cultural Health
  • [5] [Anonymous], 2024, Business Wire
  • [6] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
    Aronne, Louis J.
    Sattar, Naveed
    Horn, Deborah B.
    Bays, Harold E.
    Wharton, Sean
    Lin, Wen-Yuan
    Ahmad, Nadia N.
    Zhang, Shuyu
    Liao, Ran
    Bunck, Mathijs C.
    Jouravskaya, Irina
    Murphy, Madhumita A.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (01): : 38 - 48
  • [7] Awan O., Forbes
  • [8] Bjornstad P, 2022, NEPHROL DIAL TRANSPL, V37, pI290
  • [9] Ethnic/Racial and Geographic Disparities on Major Cardiovascular Events in Glucagon Like Peptide-1 receptor Agonists Trials: A Meta-Analysis
    Cobo, Augusto Lavalle
    Masson, Walter
    Lobo, Martin
    Barbagelata, Leandro
    Forte, Ezequiel
    Corral, Pablo
    Nogueira, Juan P.
    [J]. CURRENT PROBLEMS IN CARDIOLOGY, 2023, 48 (11)
  • [10] Cohen J., 2020, FORBES
12345